Oooh goodie! another one who only can see a downside in absolutely everything. (Because the master is in, must impress).
There is no reward in your commentary, you cannot really pretend it's balanced analysis can you?
Proper analysis balances risk vs reward. Look at the post 57207321 and read it carefully. Then get back to us about what overwhelming efficacy means in clinical trials. I will give you a hint: it means on the trials can be cut short on demonstrating this efficacy. What does that mean for your lazy claims?
Ann: Appendix 4C Quarterly Activity Report, page-83
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
-0.060(4.10%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.37 | $5.337M | 3.800M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 30254 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 11229 | 6 |
View Market Depth
| Last trade - 13.06pm 09/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |